A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors

Condition: Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Endometrial Cancer, Prostate Cancer, CCNE1 amp Solid tumor


Go To Trial Homepage